Forum Alert: Ceragenix Pharmaceuticals, Inc. will Present at the Informed Investors Biotechnology & Healthcare Investor Forum at The Hyatt Regency in San Francisco on Wednesday, December 7, 2005, 11:25 am PST

DENVER, Nov 21, 2005 -- Ceragenix Pharmaceuticals, Inc. (CGXP) will present at the following forum:

 What: Informed Investors Biotechnology & Healthcare Investor Forum
 in San Francisco

 When: December 7, 2005 @ 11:25 AM Pacific Standard Time

 Sponsors: Barron's, The Wall Street Journal and Business Wire

 Keynote Presentations: John McCamant, Editor of The Medical
                        Technology Stock Letter

                        Adam Noah, Ph.D., Vice President, Biotechnology
                        Equity Research, Merriman Curhan Ford & Co.

Forum Highlights Include: Networking session and Industry Panel Discussion at the conclusion of the presentations

Where: The Hyatt Regency Hotel, 5 Embarcadero Center, San Francisco, CA 94111

How to attend: Pre-registration is necessary. To register, contact Cary Loeser, cloeser@wilink.com, or 804-327-3407. You may also call Customer Service at 888-301-6618, or register at the following link: http://www.investorcalendar.com/IIF/CustomEvent/90563/index.asp

If you are unable to attend the live event, the forum will be archived and available via webcast at http://www.investorcalendar.com/IIF/CustomEvent/90563/index.asp

Contact Steven Porter, Chief Executive Officer, sporter@ceragenix.com, (720)946-6440

Ceragenix is a development-stage biopharmaceutical company focused on dermatology and infectious disease. Ceragenix's patented Barrier Repair Technology, invented by Dr. Peter Elias and licensed from the University of California, is the platform for the development of two prescription topical creams -- EpiCeram(TM) and NeoCeram(TM) -- that form human-identical skin barriers. Defects in the skin's barrier function play critical roles in the pathogenesis of skin diseases such as eczema, irritant contact dermatitis, and other common skin disorders. The Company's patented Cationic Steroid Antibiotic (CSA) technology provides the basis for its novel antimicrobial medical device coating that may be attached to various medical devices to provide potentially long duration antimicrobial activity. Ceragenix also plans to develop CSAs for use as topical and systemic antibiotic therapies in the treatment of skin infections (MRSA), burn wound infections, eye infections, and other indications.

CONTACT:  Informed Investors
          Cary Loeser, 804-327-3407
          cloeser@wilink.com
          http://www.informedinvestors.com